A new JAMA study of active-duty soldiers found that about one in four men had a screening testosterone below 300 ng/dL. Here is how that statistic fits with updated safety data and prescribing concerns if you are deciding whether to start testosterone replacement therapy.
What does “1 in 4 men with low testosterone” in the Army study actually mean?
The headline figure that about one in four male soldiers had low testosterone comes from a new study published in JAMA and reported in national media. Researchers measured morning testosterone in 479 active-duty men and found that 124, or roughly 25 percent, had a total testosterone under 300 ng/dL. That 300 ng/dL cut point is commonly used by professional societies as a screening threshold for possible testosterone deficiency, not as a final diagnosis.
The age breakdown matters. Among soldiers at least 30 years old, about one in three tested below 300 ng/dL. Among those under 30, about one in five fell under that level. For context, this was a fit, working population that must meet demanding physical standards. The study highlights that a low test value is not rare, even in men who are younger and active, but it does not mean that all of these men have clinical hypogonadism or need testosterone replacement therapy.
- About 25 percent of 479 soldiers had a single low morning testosterone.
- Around 33 percent of men 30 and older were below 300 ng/dL.
- Around 20 percent of men under 30 were below 300 ng/dL.
- All participants were on active duty with required fitness standards.
Why a low screening testosterone does not automatically mean you need TRT
The Army data used a single morning blood draw. Guidelines from major endocrine and urology societies are stricter. They call for at least two separate morning testosterone tests, with both results low, before a clinician can confirm biochemical hypogonadism. The Washington Post coverage of the study emphasized that testosterone levels fluctuate naturally over the day and from week to week, so a single low value can be misleading without follow-up.
In addition to repeat testing, diagnosis requires symptoms that fit low testosterone, such as reduced sex drive, erectile difficulty, fatigue, lower muscle mass, mood changes, or low bone density. Even when the number is clearly below 300 ng/dL, a clinician will usually look at other hormones, like luteinizing hormone and follicle-stimulating hormone, to classify the cause as primary, secondary, or functional. The Army study itself noted that many men with a low initial result would need confirmatory tests and clinical evaluation before any decision about testosterone replacement.
- Testosterone should be measured in the early morning, more than once.
- Both a low number and compatible symptoms are needed for diagnosis.
- Additional hormone tests can clarify the cause of low testosterone.
- Many men with one low value will not meet full criteria for TRT.
How new guideline reviews describe testosterone deficiency and therapy benefits
A recent review in a major urology journal pulled together current thinking on testosterone deficiency and treatment. It describes several patterns of low testosterone, including primary forms where the testes are not producing enough hormone, secondary forms related to pituitary or hypothalamic signals, and functional cases often linked to excess weight or chronic illness. In all of these, the combination of symptoms plus repeatedly low morning total testosterone is central to diagnosis, with free testosterone and sex hormone binding globulin testing added when needed.
The same review looked at what clinical trials show about the effects of testosterone replacement therapy. The strongest evidence is for improvements in sexual symptoms, such as libido and erectile function, and in certain blood abnormalities like anemia. Studies also suggest changes in body composition with more lean mass and less fat, and benefits for bone density and some metabolic parameters. The authors concluded that in appropriately selected men, and with regular monitoring, the risk of prostate cancer or major cardiovascular events appears low, but they stressed that treatment must be individualized.
- Hypogonadism can be primary, secondary, or functional in origin.
- Diagnosis requires symptoms plus repeated low morning testosterone.
- Evidence supports TRT benefits for sexual function and anemia.
- Body composition, metabolic health, and bone density can also change with TRT.
What recent cardiovascular safety data mean if you already have heart risks
Many men weighing testosterone therapy are understandably concerned about their heart. A structured review from an endocrinology journal examined the TRAVERSE trial, a large randomized study of men aged 45 to 80 years with confirmed hypogonadism and elevated cardiovascular risk. In that trial, testosterone treatment was found to be noninferior to placebo for major adverse cardiovascular events, with a hazard ratio close to 0.96 and a confidence interval that did not signal excess risk. In other words, within the limits of the study, adding testosterone did not clearly increase or decrease the combined rate of heart attack, stroke, and cardiovascular death.
However, the same analysis noted some secondary signals, such as slightly higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone group, although these findings were not definitive. The review concluded that clinicians should still assess individual risk factors, monitor carefully, and address modifiable contributors to low testosterone, like obesity and sleep issues, before or alongside therapy. For a man in South Florida with borderline numbers and cardiovascular concerns, it reinforces the need for a detailed discussion rather than a reflex prescription.
Why many real-world testosterone prescriptions miss testing steps and how to avoid that
While the Army study and guideline reviews describe an ideal pathway, real-world practice often looks very different. An analysis presented at a major endocrine meeting reviewed the charts of 200 men, average age just over 52, who were prescribed testosterone. Only about 12 percent had what the investigators defined as guideline-consistent evaluation: two low morning testosterone results, appropriate free or bioavailable testosterone testing when indicated, luteinizing hormone and follicle-stimulating hormone measured, and screening for contraindications.
Many men in that sample carried common midlife comorbidities such as obesity, high blood pressure, and depression, yet their records lacked the full workup before treatment was started. Most received topical testosterone formulations. For someone in Lighthouse Point or the wider South Florida area, this research highlights a clear decision point. You can ask directly whether your evaluation will include repeat morning labs, additional hormone testing, and a review of potential reversible causes. A thorough assessment slows the process slightly up front, but it helps match treatment to the right patients and may reduce avoidable risks.
How a structured TRT evaluation typically works and what affects cost and timing
Putting these studies together, a careful approach to testosterone replacement starts with symptoms, not just a number. A clinician will usually take a detailed history of sexual function, energy, sleep, mood, muscle loss, weight gain, and fracture risk, along with medications and medical conditions that can lower testosterone. Morning blood work is then ordered. If the first total testosterone result is low or borderline, a second morning draw on a different day is done, sometimes with free testosterone and sex hormone binding globulin to clarify the picture.
Further testing can include luteinizing hormone and follicle-stimulating hormone to distinguish primary from secondary hypogonadism, as well as screening for conditions that would change the risk profile. Only after that discussion and review would options like topical gels, injections, or other delivery methods be considered. The cost and timeline depend on laboratory charges, the type of formulation chosen, and how frequently monitoring labs are needed. At Rebuild Regen Medical, a physician-supervised process around testosterone replacement therapy is designed to follow this evidence-based, stepwise pattern rather than a one-visit prescription.
- undefined
- undefined
- undefined
- undefined
- undefined
- undefined
- undefined
- undefined
Frequently asked questions
- Does the new Army study mean 25 percent of men should be on testosterone therapy?
- No. The Army study reported that about 25 percent of tested soldiers had a single morning testosterone below 300 ng/dL, which is a screening threshold. Guideline-based treatment decisions still require symptoms plus at least two low morning results and additional hormone testing, so only a subset of those men would qualify for TRT after full evaluation.
- Is a total testosterone level below 300 ng/dL always considered low enough for TRT?
- The 300 ng/dL value is commonly used as a cutoff to flag possible deficiency, but it is not a stand-alone trigger for therapy. Clinicians consider the exact number, your symptoms, repeat measurements, and sometimes free testosterone before diagnosing hypogonadism and discussing TRT. Some men with borderline values and minimal symptoms are monitored rather than treated.
- How safe is testosterone replacement therapy for the heart according to newer studies?
- A large trial summarized in a recent review found that testosterone therapy was noninferior to placebo for major cardiovascular events in men with hypogonadism and elevated heart risk. There were small numerical increases in issues like atrial fibrillation and pulmonary embolism that were not conclusively significant. The takeaway is that heart risk appears acceptable when TRT is used appropriately, but careful monitoring remains important, especially in men with existing cardiovascular disease.
- What tests should I have before starting testosterone replacement therapy?
- Professional societies recommend at least two early-morning total testosterone tests showing low levels, along with evaluation of symptoms. Many men also need free testosterone, sex hormone binding globulin, and pituitary hormones such as luteinizing hormone and follicle-stimulating hormone checked. Screening for contraindications, including certain prostate, blood, and cardiovascular conditions, is another key step before prescribing TRT.
- Why do some experts say testosterone therapy is being overprescribed?
- An Endocrine Society analysis found that only about 12 percent of men who received testosterone had documentation that met full guideline criteria, including repeated low labs and hormone workup. This suggests that many prescriptions are written after limited testing or without ruling out reversible causes. For patients, it underscores the value of asking whether their evaluation aligns with current guidelines before starting long-term therapy.
- Can lifestyle changes fix low testosterone without needing TRT?
- In men with functional hypogonadism linked to obesity or chronic illness, weight loss, better sleep, and addressing underlying conditions can sometimes raise testosterone levels. The structured review on cardiovascular safety emphasizes tackling these modifiable factors before or alongside any hormone therapy. However, in men with primary or longstanding hypogonadism, lifestyle alone may not normalize levels, and a clinician can help weigh whether TRT adds value.
Talk to Rebuild Regen Medical about testosterone replacement therapy →